Here are the biggest calls on Wall Street on Friday:

KeyBanc upgrades Airbnb to overweight from sector weight

Key says it sees several positive catalysts ahead for Airbnb. “Our thesis rests on three key pillars: 1) core growth appears increasingly durable and product-led; 2) hotels are emerging as a credible second growth engine; and 3) Airbnb is positioned to be an AI beneficiary.” Read more.

Morgan Stanley names Nvidia a top pick

The firm says it’s naming Nvidia a top pick as the company is firing on all cylinders. “On our road show this week, NVDA’s CEO highlighted that recent developments in land/power/shell, financing, component constraints, and agentic all play to their strengths; we agree and are reinstating the stock as our Top Pick in semis.”

Daiwa upgrading Hewlett Packard Enterprises to outperform from neutral

Daiwa says it’s bullish on the company’s networking business. “HPE hosted a bullish Networking investor day on September 30 in California highlighting the progress and new growth rates for their Networking business. Networking is the combination of their prior business and the Juniper acquisition.”

Bank of America reiterates Apple as buy

Bank of America says its checks show Apple’s App Store revenue grew year over year. “App Store revs in F4Q26 (full quarter) increased to $8.8bn (+1.8% y/y, according to data on developer revs from SensorTower). Compared to our last iteration, this is a step up though we note historicals were restated.”

Citi reiterates Netflix as buy

Citi says it’s sticking with the stock. “Sentiment on Netflix remains subdued as engagement remains tepid. We remain more upbeat. We believe fears of churn are overblown, are encouraged by better engagement in video games, and see new tiers as a potential positive catalyst.”

Wells Fargo initiates Design Therapeutics as overweight

Wells say s Design Therapeutics is “best-in-class.” “We are positive into the 1Q27 FA update, and see blood FXN protein level increase translating to potentially best-in-disease functional improvement. We expect more pipeline appreciation to follow. Initiate OW, PT $26.”

Rothschild & Co Redburn upgrades Abbot Labs to buy from neutral

Rothschild says it sees “improved visibility.” “We have long held that Abbott Laboratories’ Medical Devices business can sustain robust growth supported by strong fundamentals and opportunities in cardiovascular and diabetes.”

Needham initiates LB Pharmaceuticals as buy

Needham says the company has blockbuster potential. “We initiate coverage on LBRX with a Buy rating and $68 PT.”

Morgan Stanley initiates Enliven Therapeutics as overweight

Morgan Stanley says the company is best-in-class. “We are initiating coverage of Enliven Therapeutics (ELVN) with an Overweight rating and a $70 price target. Enliven is a clinical-stage precision oncology company developing selective small-molecule kinase inhibitors.”

JPMorgan initiates Sable Offshore as overweight

JPMorgan says the E & P company has plenty of upside. “We initiate coverage of Sable Offshore (SOC) with an OW rating and a Dec-27 PT of $10/sh.”

Citi reiterates Strategy as buy

Citi raised its price target on Strategy to $240 per share from $136. “We reset our estimates and TP to incorporate Citi’s revised 12-month BTC forecast (base case revised 39% higher to ~$113.4k.”

Freedom Capital upgrades Cerebras to buy from hold

The firm says buy the weakness. “Over the past few days, CBRS’s investors have been rattled by news that the company’s key partner, OpenAI, is using NVIDIA’s GPUs for the frontier lab’s ‘Ultrafast’ version of its GPT-1 Sol model. CBRS’s shares have plummeted -17% likely in response to this.”

Evercore ISI reiterates SpaceX as outperform

Evercore says the Grok bot is an “underappreciated” story. “It launched almost a month before Meta’s Muse and nearly seven weeks before OpenAI’s Dots, and despite in our view being a compelling and intuitive alternative, its potential remains underappreciated within the broader SpaceX AI story.”

Bernstein reiterates Nike as outperform

Bernstein says it’s sticking with Nike following earnings on Thursday. “The biggest debate into Nike’s Q1 print was whether the new CFO would bring down FY27 numbers, clearing the decks before presenting a mid-term algo at the November investor day. Indeed, FY27 guide came in ~25% below Street, and Mgmt promised a 5-yr algo next month… not much will change until then.”